EZH2 and acute myeloid leukemia: Thus, derepression of different gene programs explains the contrasting phenotypic outcomes of Ezh2 loss of function in AML induction and maintenance and, together with the minimal toxicity of GSK343 in normal CD34+ cells (Fig. S3 d), provides some reassurances that targeting EZH2 in established AML will be a safe strategy.